Off-Label Prescribing as Treatment Complexity Evidence: A Clinical Pearl for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

Off-label prescribing occurs when a physician uses an FDA-approved medication for a condition or population not in its approved labeling. In PI cases, off-label use documents that standard treatments were insufficient and the prescriber needed to go beyond conventional approaches to manage the plaintiff's symptoms.

Off-label prescribing -- using an FDA-approved medication for an indication, dose, or patient population not specified in the drug's approved labeling -- is legal, clinically common, and often medically necessary. In personal injury litigation, the presence of off-label prescriptions in a plaintiff's pharmacy record is evidence that the plaintiff's condition was complex enough to require the prescriber to look beyond standard, on-label treatment options. It documents clinical creativity born of clinical necessity -- the injury was not responding to textbook approaches.

• Off-label prescribing is legal and accounts for an estimated 20% of all prescriptions written in the United States
• When a prescriber goes off-label, they are documenting that approved, on-label treatments were either tried and insufficient, or clinically inappropriate for the specific clinical scenario
• Off-label use requires the prescriber to exercise independent clinical judgment, often relying on clinical experience and medical literature rather than manufacturer labeling
• LienScripts identifies off-label prescribing in every case and explains its clinical significance in the MERIT (Medication Evaluation & Rationale for Injury Treatment) report
• Defense arguments that off-label medications are "experimental" or "unnecessary" misrepresent clinical reality -- off-label use is a recognized standard of care for many conditions

Why Off-Label Prescribing Indicates Complexity

Prescribers generally start with on-label options -- the medications that have specific FDA approval for the patient's diagnosed condition. When on-label options fail, the prescriber turns to off-label alternatives. This progression from on-label to off-label treatment is documented in pharmacy records and directly parallels the treatment failure narrative.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When I see off-label prescribing in a plaintiff's medication history, it tells me one of two things: either the standard treatments did not work, or the plaintiff's clinical picture was unusual enough that standard treatments were not appropriate from the start. Both scenarios document complexity that strengthens the case."

The logical chain is:

1. Prescriber starts with on-label treatment options
2. On-label options prove insufficient (lack of efficacy or intolerable side effects)
3. Prescriber exercises independent clinical judgment to select an off-label alternative
4. Off-label medication is prescribed and documented in pharmacy records
5. The off-label prescription is evidence that standard approaches failed and the injury required non-standard management

Common Off-Label Prescriptions in PI Cases

Neuropathic Pain Management

Gabapentin is one of the most widely prescribed off-label medications in personal injury cases. While FDA-approved for post-herpetic neuralgia and seizures, gabapentin is extensively prescribed off-label for:

• Trauma-related neuropathic pain
• Radiculopathy and nerve impingement
• Central sensitization pain
• Post-surgical neuropathic pain

Its widespread off-label use for trauma-related pain is supported by extensive clinical literature and is considered standard of care. However, the fact that it is technically off-label for accident-related neuropathic pain is itself evidence of complexity -- there is no single FDA-approved medication specifically indicated for "pain from a car accident." The prescriber must exercise clinical judgment to apply pharmacological tools to the patient's specific situation.

Antidepressants for Pain

Several antidepressants are used off-label for pain management:

• Amitriptyline -- FDA-approved for depression but widely used off-label for neuropathic pain, fibromyalgia, and chronic headaches
• Nortriptyline -- used off-label for neuropathic pain
• Trazodone -- FDA-approved for depression but widely used off-label for insomnia, particularly pain-related sleep disruption
• Mirtazapine -- used off-label for insomnia and appetite stimulation in patients whose pain interferes with eating and sleeping

When these medications appear in a PI plaintiff's record for pain or sleep indications, they document that conventional pain medications and sleep aids were insufficient.

Anti-Seizure Medications for Pain

Beyond gabapentin, other anti-seizure medications are used off-label for pain:

• Topiramate -- used off-label for post-traumatic migraine prophylaxis
• Carbamazepine -- used off-label for certain neuropathic pain syndromes
• Valproic acid -- used off-label for migraine prevention

These medications were developed for seizure disorders but are deployed for pain conditions when standard analgesics fail -- clear evidence of treatment complexity.

Muscle Relaxants Beyond Typical Indications

• Baclofen -- FDA-approved for spasticity from spinal cord injury or multiple sclerosis, but prescribed off-label for musculoskeletal spasm when cyclobenzaprine and tizanidine fail
• Dantrolene -- rarely used off-label for severe, refractory spasticity in PI cases

Psychiatric Medications for Trauma-Related Conditions

• Prazosin -- an alpha-blocker FDA-approved for hypertension, widely used off-label for PTSD-related nightmares
• Propranolol -- a beta-blocker used off-label for performance anxiety and PTSD symptom management
• Quetiapine -- an antipsychotic used off-label at low doses for insomnia and anxiety augmentation

Each of these off-label uses documents that conventional psychiatric treatment was insufficient for the plaintiff's accident-related psychological symptoms.

Presenting Off-Label Evidence in Demand Packages

In a demand package, off-label prescriptions should be highlighted as evidence of clinical complexity, not questioned as inappropriate care:

"The plaintiff's regimen includes amitriptyline 50mg at bedtime. While FDA-approved for depression, amitriptyline was prescribed in this case for the off-label indication of neuropathic pain management. The treating physician turned to this off-label approach after standard neuropathic agents -- gabapentin at maximum dose -- failed to adequately control the plaintiff's radiating nerve pain. The use of off-label prescribing documents that the plaintiff's pain was refractory to standard first-line treatments and required the prescriber to exercise additional clinical judgment in selecting alternative pharmacological approaches."

The MERIT Report and Off-Label Context

LienScripts includes off-label identification in every MERIT report. The pharmacist-authored narrative explains which medications are being used off-label, what the off-label indication is, and why the prescriber's decision to go off-label reflects clinical complexity. This context prevents defense counsel from mischaracterizing off-label use as inappropriate or experimental.

Countering Defense Arguments

"The medication is not FDA-approved for this condition."

Off-label prescribing is legal, ethical, and clinically common. The FDA itself acknowledges that once a medication is approved, healthcare providers may prescribe it for uses not in the labeling based on their clinical judgment. The absence of FDA approval for the specific indication does not make the prescribing inappropriate -- it makes it evidence of clinical complexity.

"The prescriber is practicing outside standard of care."

For many off-label uses -- gabapentin for trauma-related neuropathic pain, amitriptyline for chronic pain, prazosin for PTSD nightmares -- the off-label use is itself the standard of care, supported by extensive clinical literature and practice guidelines. A pharmacist expert can testify to the clinical appropriateness of each off-label prescription.

"The medication is experimental and should not be included in damages."

Off-label is not experimental. Experimental refers to medications not yet FDA-approved for any indication. Off-label medications are FDA-approved and marketed -- they are simply being applied to a condition outside their labeled indications based on clinical evidence and prescriber judgment. The distinction is clinically and legally significant.

Multiple Off-Label Medications

When a plaintiff's regimen includes multiple off-label medications, the complexity argument compounds. A regimen of gabapentin (off-label for trauma-related neuropathic pain), amitriptyline (off-label for pain), and prazosin (off-label for PTSD nightmares) documents a clinical picture so complex that the prescriber needed to go beyond standard labeling across multiple medication classes. This is not a plaintiff with a simple injury treatable by the book. This is a plaintiff whose injury required the prescriber to draw on the full breadth of clinical pharmacology.

The Clinical Pearl

Off-label prescribing in a plaintiff's pharmacy record is a marker of treatment complexity, not inappropriate care. It documents that the prescriber exhausted or bypassed standard options and exercised independent clinical judgment to find medications that could manage the plaintiff's specific, complex clinical picture. Attorneys who understand and present this context transform what defense might characterize as "unapproved treatment" into compelling evidence of injury severity and clinical difficulty.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that identifies every off-label prescription and explains its clinical rationale in the context of the plaintiff's injury.

Related Resources

• Medication Switches Prove Treatment Failure -- How switching medications documents failed prior treatments
• Co-Prescribed Medications Prove Injury Severity -- Using medication combinations to demonstrate multi-system injury